Mission Cure Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -30.41%
- Profit Growth -34.34%
- Ebitda -33.14%
- Net Worth 23.15%
- Total Assets -8.55%
About Mission Cure Pharma
Mission Cure Pharma Private Limited (MCPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 October 2013 and has a history of 11 years and three months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Devangkumar Shah and Udayan Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233GJ2013PTC077247
-
Company No.
077247
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Oct 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Mission Cure Pharma Private Limited offer?
Mission Cure Pharma Private Limited offers a wide range of products and services, including Vitamins & Supplements, Multivitamins.
Who are the key members and board of directors at Mission Cure Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devangkumar Shah
|
Director | 17-Oct-2013 | Current |
|
Udayan Shah
|
Director | 09-Jun-2017 | Current |
Financial Performance of Mission Cure Pharma.
Mission Cure Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 30.41% decrease. The company also saw a substantial fall in profitability, with a 34.34% decrease in profit. The company's net worth Soared by an impressive increase of 23.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mission Cure Pharma?
In 2021, Mission Cure Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Djs Property Solution Private LimitedDevangkumar Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mission Cure Pharma?
Unlock and access historical data on people associated with Mission Cure Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mission Cure Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mission Cure Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
